Fate Therapeutics Inc (NAS:FATE)
$ 3.245 0.075 (2.37%) Market Cap: 369.38 Mil Enterprise Value: 77.67 Mil PE Ratio: 0 PB Ratio: 0.87 GF Score: 57/100

Fate Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 11, 2021 / 04:30PM GMT
Release Date Price: $97.66 (+8.69%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everybody. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech analysts here at Barclays. And I think -- I just want to thank everybody for joining us -- for taking time out of their day. If you have questions for me, kind of know-how to reach me, [email protected], or you can ping me on Bloomberg.

And it gives me great pleasure today to introduce the team from Fate Therapeutics. So we've got Scott Wolchko and Ed Dulac, CFO. And so just as an introductory question I've asked, I think I asked you this question multiple times. And many of my questions -- many have might come to this multiple times as well. Just the point -- the differentiation of Fate in the oncology space kind of -- what do you kind of view as your core competencies? And then we'll kind of dive into questions.

J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director

Sure. So cell-based cancer immunotherapy company.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot